Delfi Diagnostics said New York State Department of Health approval cleared its FirstLook Lung laboratory-developed test for blood-based lung cancer screening. The company can now offer its cfDNA-based liquid biopsy assay in all 50 states and is pursuing U.S. FDA approval. Delfi CEO Susan Tousi positioned the decision around access, citing a near-threefold increase in screening uptake in a nearly 3,000-patient clinical study earlier this month. The company framed New York’s review process as a marker of adherence to clinical laboratory standards. For screening developers, state-level clearances can rapidly expand patient reach while providing evidence streams for federal review.